Login
By Stephen Prager
In what advocates for lower drug prices call “a match made in hell,” one of the pharmaceutical industry’s most powerful lobbying groups is tapping a former Republican leader in the U.S. House of Representatives to head its political operations.
Pharmaceutical Research and Manufacturers of America (PhRMA) named former Rep. Eric Cantor (R-Va.) as its president and CEO on Tuesday amid what is shaping up to be a major fight over the government’s ability to regulate prescription drug prices.
Cantor served in Congress from 2001 to 2014 and was named House majority leader in 2011. He resigned in 2014 after losing his Republican primary in a stunning upset to the Tea Party-backed former Rep. Dave Brat.
According to recent polling from KFF, more than half of U.S. adults say they worry about affording prescription drugs and nearly three-quarters say the government should do more to limit prices.
PhRMA emphasized that Cantor’s appointment to replace the outgoing CEO Stephen Ubl comes at “a pivotal moment for America’s biopharmaceutical industry.”
It is certainly spending like it. As Politico reported on Tuesday, pressure from voters to address the affordability of prescription drugs has been met with an unprecedented lobbying blitz by PhRMA, which poured a record $38 million into efforts to keep Capitol Hill in line.
PhRMA said Cantor’s “global business acumen coupled with policy and political experience at the highest levels of government make him an ideal person to lead PhRMA during this critical next chapter.”
Peter Maybarduk, the access-to-medicines director for the consumer watchdog group Public Citizen, agreed that Cantor was a perfect fit for PhRMA, but for very different reasons.
“Cantor, like PhRMA, is an experienced reverse Robin Hood, legislating money away from working families and toward giant corporations,” Maybarduk said.
During his tenure in Congress, Cantor received roughly $900,000 from the pharmaceutical and health product industry, putting him 19th among all House candidates between 1999 and 2018, according to a JAMA Internal Medicine study of data from the Center for Responsive Politics.
That spending paid dividends, with Cantor voting against legislation aimed at lowering prescription drugs — including one bill in 2003 that would have allowed Americans to import low-cost prescription drugs from abroad and another in 2007 that would have required the federal government to negotiate drug prices for Medicare recipients.
Originally published by Common Dreams.
Stephen Prager is a staff writer for Common Dreams.
